ArticleFrontiers in nutrition2024
Efficacy and safety of
Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Microbiota-based interventions for autism spectrum disorder: a systematic review of efficacy and clinical potential.Frontiers in microbiology · 2025Pooled it
- Review
- Metabolic shifts driven by host-microbial interactions.The FEBS journal · 2026Review
- Effect of Probiotics on the Gut-Mammary Pathway: Implications on Infant Microbiota Transfer and Development.Current nutrition reports · 2026Review
- Limosilactobacillus reuteri LR-99 Modulates Gut Microbiota and Core Symptoms in Children with Autism Spectrum Disorder: A Single-arm Pilot Study.Probiotics and antimicrobial proteins · 2026Article
- Effects of nutritional supplementation on social impairment and behavioral dysregulation in autism spectrum disorder: a network meta-analysis.BMC psychiatry · 2026Article
- Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges.World journal of clinical pediatrics · 2026Article
- The Gut Microbiota and Autism Spectrum Disorder: Current Research and Therapeutic Insights.Behavioral sciences (Basel, Switzerland) · 2026Review
- The Gut Microbiota-Tryptophan-Brain Axis in Autism Spectrum Disorder: A New Frontier for Probiotic Intervention.Microorganisms · 2026Review
- Safety Assessment of Two Human Fecal Bacteroides Strain Isolates in Immunodeficient Mice.Probiotics and antimicrobial proteins · 2026Article
- The Gut-Brain Axis in Autism: Inflammatory Mechanisms, Molecular Insights, and Emerging Microbiome-Based Therapies.Molecular neurobiology · 2025Review
- Lactoferrin-osteopontin complexes: insights into intestinal organoid bioavailability and gut microbiota modulation.Communications biology · 2025Article
- Mechanistic Links Between Gut Dysbiosis, Insulin Resistance, and Autism Spectrum Disorder.International journal of molecular sciences · 2025Review
- Article
- Article
- Gut microbiota diversity is altered in a sex-dependent manner in Shank3B heterozygote mice.Frontiers in microbiomes · 2025Article
- Therapeutic efficacy of fecal microbiota transplantation in severe food intolerance: a case report.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical utility of Methods: We examined 60 children aged 2-10 years diagnosed with ASD, and participants received either BF839 powder (10 g/bar with ≥10 Results: Compared with the placebo group, the BF839 group showed significant improvement in the ABC body and object use scores at week 16, which was more pronounced in children with ASD aged <4 years. Among children with a baseline CARS score ≥30, the BF839 group showed significant improvements at week 16 in the ABC total score, ABC body and object use score, CARS score, and GSRS score compared to the placebo group. Only two patients (6.67%) in the BF839 group experienced mild diarrhea. Compared with baseline and placebo group levels, the BF839 group showed a significant post-intervention increase in abundance of Conclusion: BF839 significantly and safely improved abnormal behavior and gastrointestinal symptoms in children with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.